BioWorld

Feb. 14, 2006

Greenwood Planning More Time Spent On Capitol Hill

Affymax Partners Anemia Drug In Japan For $102M

Less than a month after Affymax Inc. started the fourth Phase II trial of its lead product, Hematide, to treat anemia, the company signed a partnership deal in Japan worth up to $102 million. (BioWorld Today) Read More

Replidyne Gets $50M Up Front Through Forest Collaboration

Novacea’s IPO Seeks $75M To Fund Late-Stage DN-101

Avastin Study Suspended Because Of Patient Deaths

Caliper Buying Xenogen: $80M In Stock, Warrants

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...